[Skip to Navigation]
Sign In
Comment & Response
March 12, 2020

Metformin Plus Tyrosine Kinase Inhibitors in Epidermal Growth Factor Receptor–Mutated Non–Small Cell Lung Cancer—Reply

Author Affiliations
  • 1Thoracic Oncology Unit, Instituto Nacional de Cancerología (INCan), México City, México
JAMA Oncol. 2020;6(5):782-783. doi:10.1001/jamaoncol.2020.0062

In Reply We read with great interest the letter by Gao et al in which several issues are raised regarding our randomized clinical trial (RCT),1 particularly considering the negative results of a double-blind RCT, the Combined Gefitinib and Metformin Therapy study.2 Importantly, all patients were randomized as per protocol. Nonetheless, at the time of the submission deadline for abstracts for the 2018 American Society of Clinical Oncology annual meeting, the data capture in the database was incomplete, and the analysis was performed with the information captured to that date, though all patients had been recruited at this point. In the following weeks, all data were captured in time to be analyzed and presented in a publicly available poster during the meeting. The information regarding allocation presented in the poster and the published article is exactly the same.

Add or change institution